Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

CDC25 phosphatases in cancer cells: key players? Good targets?

Boutros R, Lobjois V, Ducommun B.

Nat Rev Cancer. 2007 Jul;7(7):495-507. Review.

PMID:
17568790
2.

Cdc25 phosphatases and cancer.

Kristjánsdóttir K, Rudolph J.

Chem Biol. 2004 Aug;11(8):1043-51. Review.

3.

Cell cycle control by the CDC25 phosphatases.

Aressy B, Ducommun B.

Anticancer Agents Med Chem. 2008 Dec;8(8):818-24. Review.

PMID:
19075563
4.

The when and wheres of CDC25 phosphatases.

Boutros R, Dozier C, Ducommun B.

Curr Opin Cell Biol. 2006 Apr;18(2):185-91. Review.

PMID:
16488126
5.

Cdc25 phosphatases: structure, specificity, and mechanism.

Rudolph J.

Biochemistry. 2007 Mar 27;46(12):3595-604. Review.

PMID:
17328562
6.

[Role of CDC25 phosphatases in the control of proliferation].

Davezac N, Ducommun B, Baldin V.

Pathol Biol (Paris). 2000 Apr;48(3):182-9. Review. French.

PMID:
10858952
7.

CDC25A and B dual-specificity phosphatase inhibitors: potential agents for cancer therapy.

Lavecchia A, Di Giovanni C, Novellino E.

Curr Med Chem. 2009;16(15):1831-49. Review.

PMID:
19442149
8.

CDC25 dual-specificity protein phosphatases: detection and activity measurements.

Dalal SN, Volkening M.

Methods Mol Biol. 2005;296:329-44.

PMID:
15576942
9.

Inhibitors of the CDC25 phosphatases.

Prevost GP, Brezak MC, Goubin F, Mondesert O, Galcera MO, Quaranta M, Alby F, Lavergne O, Ducommun B.

Prog Cell Cycle Res. 2003;5:225-34. Review.

PMID:
14593717
10.

CDC25A: a rebel within the CDC25 phosphatases family?

Fernandez-Vidal A, Mazars A, Manenti S.

Anticancer Agents Med Chem. 2008 Dec;8(8):825-31. Review.

PMID:
19075564
11.

Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.

Lavecchia A, Di Giovanni C, Novellino E.

Expert Opin Ther Pat. 2010 Mar;20(3):405-25. doi: 10.1517/13543771003623232. Review.

PMID:
20166845
12.
13.

Differential regulation of growth and checkpoint control mediated by a Cdc25 mitotic phosphatase from Pneumocystis carinii.

Gustafson MP, Thomas CF Jr, Rusnak F, Limper AH, Leof EB.

J Biol Chem. 2001 Jan 5;276(1):835-43.

PMID:
11029470
14.

CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability.

Ray D, Kiyokawa H.

Cancer Res. 2008 Mar 1;68(5):1251-3. doi: 10.1158/0008-5472.CAN-07-5983. Review.

15.

What if higher plants lack a CDC25 phosphatase?

Boudolf V, Inzé D, De Veylder L.

Trends Plant Sci. 2006 Oct;11(10):474-9.

PMID:
16949857
16.

Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines.

Löffler H, Syljuåsen RG, Bartkova J, Worm J, Lukas J, Bartek J.

Oncogene. 2003 Nov 6;22(50):8063-71.

PMID:
14603247
17.

14-3-3 Proteins--a focus on cancer and human disease.

Wilker E, Yaffe MB.

J Mol Cell Cardiol. 2004 Sep;37(3):633-42. Review.

PMID:
15350836
18.

Dynamic control of cell cycle and growth coupling by ecdysone, EGFR, and PI3K signaling in Drosophila histoblasts.

Ninov N, Manjón C, Martín-Blanco E.

PLoS Biol. 2009 Apr 7;7(4):e1000079. doi: 10.1371/journal.pbio.1000079.

19.

CDC25 phosphatase inhibitors: an update.

Lavecchia A, Di Giovanni C, Novellino E.

Mini Rev Med Chem. 2012 Jan;12(1):62-73. Review.

PMID:
22070688
20.

Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.

Lavecchia A, Coluccia A, Di Giovanni C, Novellino E.

Anticancer Agents Med Chem. 2008 Dec;8(8):843-56. Review.

PMID:
19075567
Items per page

Supplemental Content

Support Center